Results 71 to 80 of about 8,117 (271)

Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study

open access: yesFrontiers in Immunology, 2023
BackgroundEosinophilic granulomatosis with polyangiitis (EGPA) is a rare vasculitis characterized by asthma, systemic manifestations, and blood and tissue eosinophilia.ObjectiveTo assess the effectiveness and safety of mepolizumab (anti-IL-5) and ...
Santi Nolasco   +20 more
doaj   +1 more source

We Have to Learn to Do Without Knowing Enough: Anti-Eosinophilic Treatments for Severe Asthma [PDF]

open access: yes, 2018
Interleukin.5 (IL.5) is the main eosinophilic cytokine that promotes the differentiation, survival, and activation of eosinophils, which are the key inflammatory cells in severe eosinophilic asthma .Thus, it is no surprise that ...
4,   +3 more
core   +1 more source

Safety and efficacy of monoclonal antibodies targeting IL-5 in severe eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials

open access: yesHealth Sciences Review, 2023
Background: Recently, mepolizumab and benralizumab have been approved for the treatment of severe eosinophilic asthma. Objective: Thus, the main objective of the current study was to find out the exact efficacy and safety profile of mepolizumab and ...
Noor Alam, S. Latha, Anoop Kumar
doaj  

Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposis

open access: yesRespirology (Carlton South. Print)
Several randomized controlled trials (RCTs) have shown that benralizumab is characterized by a good profile of efficacy and safety, thereby being potentially able to elicit clinical remission on‐treatment of severe eosinophilic asthma (SEA).
C. Pelaia   +27 more
semanticscholar   +1 more source

Reductions in eosinophil biomarkers by benralizumab in patients with asthma [PDF]

open access: yesRespiratory Medicine, 2016
Eosinophilic inflammation is frequently associated with increased asthma severity. Benralizumab is a humanized, afucosylated, anti-interleukin-5Rα monoclonal antibody that selectively depletes eosinophils and basophils through enhanced antibody-dependent cell-mediated cytotoxicity.To study effects of benralizumab on eosinophil counts and activity ...
Koustubh Ranade   +3 more
openaire   +3 more sources

Anaphylaxis to three humanized antibodies for severe asthma: a case study

open access: yesAllergy, Asthma & Clinical Immunology, 2020
Background Omalizumab, mepolizumab, benralizumab, and dupilumab are the currently available biologics used to treat asthma in Japan. Anaphylaxis following treatment with mepolizumab or benralizumab is considered rare. Case presentation We report the case
Koichi Jingo   +9 more
doaj   +1 more source

Severe Toxic Epidermal Necrolysis and Drug Reaction with Eosinophilia and Systemic Symptoms Overlap Syndrome Treated with Benralizumab: A Case Report [PDF]

open access: yes, 2022
TEN/DRESS overlap syndrome can be difficult to diagnose, especially if it is masked by comorbidities in critically ill patients in intensive care units. The existing therapy for the two conditions is also a major challenge for the treating team.
Bader, Patrick R   +4 more
core   +1 more source

Benralizumab monotherapy was insufficient to induce remission in patients with active eosinophilic granulomatosis with polyangiitis

open access: yesRespiratory Medicine Case Reports, 2022
Eosinophils play an important pathogenetic role in the development of eosinophilic granulomatosis with polyangiitis (EGPA). EGPA has long been treated with systemic corticosteroids and immunosuppressive agents.
Osamu Matsuno, Seijiro Minamoto
doaj  

Efficacy and safety of benralizumab in elderly patients with severe eosinophilic asthma

open access: yesEuropean Clinical Respiratory Journal
Background Biologics are the important drugs for severe asthma, but clinical trials included few elderly patients. Data on the safety and efficacy of benralizumab in elderly asthma patients are limited.Methods This clinical study was a multicentre ...
Kohei Somekawa   +19 more
doaj   +1 more source

Home - About - Disclaimer - Privacy